

# UCLA

## UCLA Previously Published Works

### Title

Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survival

### Permalink

<https://escholarship.org/uc/item/2fz3k25k>

### Journal

Signal Transduction and Targeted Therapy, 3(1)

### ISSN

2095-9907

### Authors

Rozengurt, Enrique  
Sinnott-Smith, James  
Eibl, Guido

### Publication Date

2018

### DOI

10.1038/s41392-017-0005-2

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed



## REVIEW ARTICLE OPEN

# Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survival

Enrique Rozengurt<sup>1,2,3</sup>, James Sinnett-Smith<sup>1,2</sup> and Guido Eibl<sup>1,2,4</sup>

Pancreatic ductal adenocarcinoma (PDAC) is generally a fatal disease with no efficacious treatment modalities. Elucidation of signaling mechanisms that will lead to the identification of novel targets for therapy and chemoprevention is urgently needed. Here, we review the role of Yes-associated protein (YAP) and WW-domain-containing Transcriptional co-Activator with a PDZ-binding motif (TAZ) in the development of PDAC. These oncogenic proteins are at the center of a signaling network that involves multiple upstream signals and downstream YAP-regulated genes. We also discuss the clinical significance of the YAP signaling network in PDAC using a recently published interactive open-access database ([www.proteinatlas.org/pathology](http://www.proteinatlas.org/pathology)) that allows genome-wide exploration of the impact of individual proteins on survival outcomes. Multiple YAP/TEAD-regulated genes, including *AJUBA*, *ANLN*, *AREG*, *ARHGAP29*, *AURKA*, *BUB1*, *CCND1*, *CDK6*, *CXCL5*, *EDN2*, *DKK1*, *FOSL1*, *FOXM1*, *HBEGF*, *IGFBP2*, *JAG1*, *NOTCH2*, *RHAMM*, *RRM2*, *SERP1*, and *ZWILCH*, are associated with unfavorable survival of PDAC patients. Similarly, components of AP-1 that synergize with YAP (*FOSL1*), growth factors (TGF $\alpha$ , EPEG, and HBEGF), a specific integrin (*ITGA2*), heptahelical receptors (*P2Y<sub>2</sub>R*, *GPR87*) and an inhibitor of the Hippo pathway (*MUC1*), all of which stimulate YAP activity, are associated with unfavorable survival of PDAC patients. By contrast, YAP inhibitory pathways (STRAD/LKB-1/AMPK, PKA/LATS, and TSC/mTORC1) indicate a favorable prognosis. These associations emphasize that the YAP signaling network correlates with poor survival of pancreatic cancer patients. We conclude that the YAP pathway is a major determinant of clinical aggressiveness in PDAC patients and a target for therapeutic and preventive strategies in this disease.

*Signal Transduction and Targeted Therapy* (2018)3:11 <https://doi.org/10.1038/s41392-017-0005-2>

## INTRODUCTION

Pancreatic cancer, of which pancreatic ductal adenocarcinoma (PDAC) represents the most common histological subtype, is one of the most lethal human diseases, with overall 5-year survival rates of 7% and a median survival period of 4–6 months<sup>1</sup>. The incidence of this disease in the United States is estimated to increase to 53,670 new cases in 2017. Indeed, deaths due to PDAC are projected to increase dramatically, making the disease the second leading cause of cancer-related deaths in the USA before 2030<sup>2</sup>. Novel targets and agents for therapy and chemoprevention are urgently needed and will most likely arise from a more detailed understanding of the signaling mechanisms that stimulate the promotion and progression of sub-malignant (initiated) cells into pancreatic cancer cells and from the identification of modifiable risk factors for PDAC. Identification of the molecular mechanisms of PDAC promotion and drug resistance will clearly guide the discovery of novel targets, prognostic markers, agents for therapy and prevention and will identify effective signature markers for use in specific and personalized therapeutic procedures.

PDAC arises from the evolution of precursor lesions, the most common of which are pancreatic intraepithelial neoplasias


(PanINs). Progression from these noninvasive ductal lesions to in situ carcinomas and invasive cancers is associated with the accumulation of genetic alterations, including activation of mutations in the *KRAS* oncogene, which are widely accepted to represent an initiating event<sup>3</sup>. Accordingly, exome sequencing has established *KRAS* to be the most frequently mutated gene in PDAC (~95%)<sup>4, 5</sup>. The majority of all missense *KRAS* mutations in PDAC occur at position G12, with a G12D single amino acid substitution being the most prevalent. These mutations prevent interactions between *KRAS*-GTP and *KRAS* GTPase-activating proteins (GAPs), thus leading to prolonged activation of *KRAS* and thereby to the activation of downstream signaling effectors, the best characterized of which are the RAF/MEK/ERK and PI3K/AKT/mTOR pathways<sup>6, 7</sup>. Genetically engineered mouse models that recapitulate many features of the human disease have defined a critical role for *Kras*<sup>G12D</sup> in the initiation and maintenance of PDAC<sup>3, 8, 9</sup>. The progression of pancreatic carcinogenesis requires stimulation of a set of signaling pathways that lead to sustained cell proliferation<sup>4</sup>. Although, a *KRAS* mutation is an early and necessary event in the development of PDAC, it is not sufficient to promote the complete carcinogenic process. Activation of other pathways by additional mutations, including mutations in tumor suppressor genes, such

<sup>1</sup>Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 9005, USA; <sup>2</sup>CURE: Digestive Diseases Research Center, University of California, Los Angeles, CA 9005, USA; <sup>3</sup>Molecular Biology Institute, University of California, Los Angeles, CA 9005, USA and <sup>4</sup>Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 9005, USA

Correspondence: Enrique Rozengurt ([erozengurt@mednet.ucla.edu](mailto:erozengurt@mednet.ucla.edu)) or James Sinnett-Smith ([jsinnett@mednet.ucla.edu](mailto:jsinnett@mednet.ucla.edu)) or Guido Eibl ([geibl@mednet.ucla.edu](mailto:geibl@mednet.ucla.edu))

Received: 30 October 2017 Revised: 27 November 2017 Accepted: 13 December 2017

Published online: 20 April 2018



**Fig. 1** Hippo signaling phosphorylates YAP and regulates its nuclear/cytoplasmic distribution. When Hippo signaling is active (e.g., in response to cell density, polarity signals, or mechanical cues) the Mst1/2 kinases, in complex with Sav1, phosphorylate and activate Lats1/2 in complex with its regulatory protein MOB1/2. In addition to Mst1/2, MAP4Ks act as alternative kinases that phosphorylate Lats1/2. In turn, Lats1/2 phosphorylates YAP on highly conserved residues (in red) located within a consensus sequence that is phosphorylated by Lats1/2 (HXRXXS). The phosphorylation of YAP at Ser-127 promotes its cytoplasmic retention, whereas phosphorylation at Ser-397 induces degradation. When the Hippo pathway is off, YAP is dephosphorylated and translocated into the nucleus where YAP binds and activates the TEAD transcription factors and stimulates the expression of multiple genes. Additional details are provided in the text

as *TP53*, one of the most frequently mutated genes in human cancer, *CDKN2A*, the gene encoding p16 and p14, and *SMAD4* and/or environmental stimuli (obesity, type 2 diabetes mellitus) are required for the promotion of invasive PDAC. This article highlights a striking association between a signal transduction network and the overall survival of patients with PDAC.


**THE HIPPO/YAP/TAZ PATHWAY AND PDAC**

The transcriptional co-activators yes-associated protein (YAP)<sup>10</sup> and its paralog WW-domain-containing Transcriptional co-Activator with a PDZ-binding motif (TAZ)<sup>11</sup> are attracting intense attention as fundamental points of convergence and intersection of many signal transduction pathways that are implicated in the regulation of development, metabolism, organ-size, positional sensing, tissue regeneration and tumorigenesis<sup>12-14</sup>. Indeed, multiple products of the YAP/TEAD-regulated gene network have a major impact on these important processes, and YAP and TAZ are increasingly recognized as potent oncogenes in many cancer types<sup>15</sup>, especially in PDAC<sup>16-19</sup>. After a succinct overview of the YAP/TAZ network in PDAC, the basic tenet of this article will be to emphasize the association between the expression of each element of the network and patient overall survival. Therefore, this review integrates signal transduction and patient survival, and thus differs in focus from many recent excellent reviews on the Hippo/YAP/TAZ pathway that are available in the literature<sup>12-15, 20</sup>.

It is widely recognized that a major factor in the regulation of YAP/TAZ activity is the Hippo pathway, which was originally identified in *Drosophila*<sup>12</sup>. Canonical Hippo signals are transduced through a serine/threonine kinase cascade, wherein Mst1/2 kinases, in complex with Sav1, phosphorylate and activate Lats1/2 in complex with its regulatory protein MOB1/2 (Fig. 1). In addition to Mst1/2, Hppy/MAP4Ks were identified as alternative kinases that phosphorylate Lats1/2<sup>21</sup>. In turn, Lats1/2 phosphorylates YAP and TAZ, two major downstream effectors of the Hippo pathway and novel sensors of the mevalonate and glycolytic pathways<sup>13, 22, 23</sup>. Structurally, YAP and TAZ share nearly half of their overall amino acid sequences, and have very similar

topologies and highly conserved residues that are located within a consensus sequence that is phosphorylated by Lats1/2 (HXRXXS). The phosphorylation of YAP by Lats1/2 at Ser-127 and Ser-397 (and equivalent residues in TAZ) restricts its cellular localization to the cytoplasm and reduces the protein's stability (Fig. 1). When the Hippo pathway is not functional, YAP and TAZ are dephosphorylated and translocated to the nucleus where they bind to and activate a number of transcription factors, primarily the TEA-domain DNA-binding transcription factors (TEAD 1-4). In this manner, nuclear YAP and TAZ promote the expression of multiple genes (Fig. 1). Accordingly, YAP and TAZ display a degree of functional redundancy<sup>15, 20</sup> but also differ in a number of ways. For example, YAP negatively regulates TAZ, while TAZ expression levels do not modulate YAP levels<sup>24</sup>. TAZ is more unstable than YAP, thus these oncogenic proteins often are differentially expressed in different cancer cell types<sup>25</sup>. Therefore, activation of the tumor suppressor Hippo pathway in response to multiple environmental cues, including cell/cell contacts, cell polarity and mechanical tension, potentially inhibits the transcriptional co-activator activity of YAP and TAZ and leads to the degradation of TAZ<sup>12, 15, 26-28</sup>.

By contrast, multitude upstream pathways positively control YAP/TAZ transcriptional co-activator activity. These include signals mediated by ligand-activated G protein-coupled receptors (GPCRs), tyrosine kinase receptors, integrins and mechanical cues (Fig. 2). A variety of signaling pathways that are activated by these receptors, including PI3K, mTOR, PKD, and Rho/actin cytoskeleton, feed into the YAP/TAZ pathway<sup>12, 15, 26-28</sup>. For example, a recent study with human PDAC cells demonstrated that crosstalk between insulin/IGF-1 receptor and GPCR systems<sup>29, 30</sup> regulates YAP localization, phosphorylation, and transcriptional co-activator activity through PI3K and PKD<sup>31</sup>. Accordingly, recent studies with other cell types demonstrated that PI3K inhibits the activity of the Hippo pathway<sup>32, 33</sup>, thereby promoting YAP activity. Other studies have demonstrated that PKD, a key node downstream of GPCRs<sup>34, 35</sup>, stimulates the nuclear localization of YAP and the activation of YAP/TEAD-regulated gene expression, most likely by stabilizing the actin cytoskeleton<sup>28</sup>. Thus, extracellular stimuli can



**Fig. 2** YAP is at the epicenter of a signaling network. Growth factors (TGF $\alpha$ , EPEG, and HBEGF) induce EGFR signaling leading to KRAS activation, which in turn, stimulates YAP activation and increased expression. Other tyrosine kinase receptors, a specific integrin (*ITGA2*), multiple GPCRs, an inhibitor of Hippo pathway (*MUC1*) and actin polymerization via multiple pathways also stimulate YAP activity. Activation of YAP stimulates its coupling with TEAD, thereby promoting the expression of multiple YAP/TEAD-regulated genes that were identified in screens in different cell types. Reference to the study or studies connecting each gene to YAP/TAZ, as well as further details concerning the network are in the text

control YAP/TAZ activity via inhibition of the Hippo pathway and/or stabilization of the actin cytoskeleton, thereby regulating a complex program of gene expression (Fig. 2). A recent report indicated that in addition to YAP and TAZ, the TEAD transcription factors also shuttle between the nucleus and the cytoplasm and that environmental stress promotes the cytoplasmic translocation of TEAD via p38 MAPK in a Hippo-independent manner, thus identifying an additional level of regulation<sup>36</sup>.

The YAP/TAZ pathway assumes an added importance in PDAC because YAP is also a key downstream target of KRAS signaling<sup>16</sup> that is required for acinar-to-ductal metaplasia (ADM) and PanIN progression into PDAC in genetically engineered mouse models<sup>16, 17</sup>. YAP is also a major mediator of pro-oncogenic mutant p53, resistance to RAF/MEK inhibitors and chemotherapy in PDAC<sup>37, 38</sup>, and TAZ supports development of pancreatic cancer<sup>39</sup>. Conversely, mutants that render p53 as a super suppressor of pancreatic cancer act via inactivation of Yap<sup>40</sup>. It is of interest that pancreas-specific deletion of *Yap* did not affect normal pancreatic development and endocrine functions, but blocked the progression of *Kras*<sup>G12D</sup>-induced evolution of PanINs to overt PDAC<sup>16</sup>.

In addition to the rapid regulation of YAP activity via phosphorylation and localization, additional pathways and epigenetic events regulate the level of YAP/TAZ protein expression. In this regard, the RAS pathway promotes YAP1 stability independent of the Hippo pathway through down regulation of the ubiquitin ligase complex substrate recognition factors SOCS5/6, thereby increasing YAP stability<sup>41</sup>. A recent study demonstrated that eIF5A (eukaryotic translation initiation factor 5A), which is up-regulated by KRAS in PDAC and in KC mice (i.e., mice harboring a *Kras*<sup>G12D</sup>), increases the tyrosine kinase PEA1. In turn, the eIF5A/PEAK1 axis enhances the expression of YAP<sup>42</sup>. It is also relevant that YAP and mTORC1 form an amplification loop that enhances

the expression of YAP protein. Specifically, YAP stimulates mTORC1 via down regulation of phosphatase and tensin homolog (PTEN) and increases amino acid (leucine) transport<sup>43</sup>. In turn, the activation of mTORC1 leads to the accumulation of YAP through impaired autophagy<sup>44</sup>. The positive feedback loop between YAP and mTORC1 increases YAP activity and expression.

Recent studies have demonstrated that amplification and overexpression of YAP could substitute for mutant *Kras* in murine cancers<sup>19, 45</sup>. These findings raise the important notion that YAP not only acts downstream of *Kras* but also that hyper-activation and expression of YAP can circumvent the need for *Kras* mutant expression in PDAC<sup>3, 19</sup>. An important feature of PDAC is the recruitment of immune-suppressive leukocytes, including myeloid-derived suppressor cells and tumor-associated macrophages, that contribute to immune evasion<sup>3</sup>. Recently, YAP has been shown to play a critical role in promoting an immunosuppressive microenvironment via the production of multiple cytokines in PDAC<sup>46</sup> and in other cancers<sup>47</sup>. Thus, there is substantial evidence from preclinical studies indicating that YAP/TAZ is at the epicenter of a signaling network that is of crucial importance in the development of PDAC. Our next objective is to focus on the importance of the YAP/TAZ pathway in human PDAC.

#### CLINICAL SIGNIFICANCE OF YAP: A PROGNOSTIC MARKER IN PDAC


To assess the significance of the YAP pathway in human PDAC, we will discuss the importance of YAP as a prognostic marker of survival in patients with PDAC. A number of studies have indicated that YAP and TAZ are overactive in tumor samples from PDAC patients, as judged by their expression and or localization<sup>18, 19, 39</sup>. Furthermore, a recent report identified YAP expression as an independent prognostic marker for the overall survival of PDAC

patients and its association with liver metastasis<sup>48</sup>. If YAP plays a critical role in the survival of PDAC patients, it is plausible that upstream and downstream elements of the network, as well as regulators of YAP activity that have been identified in a variety of cells, are also likely to be associated with survival of patients with PDAC, and can serve as prognostic markers. Given its important translational implications, we explored this proposition using a recently published interactive open-access database ([www.proteinatlas.org/pathology](http://www.proteinatlas.org/pathology)) to perform correlation analyses based on mRNA expression levels of genes of the YAP pathway in PDAC tissue and the clinical outcome (survival) of the patients<sup>49</sup>. The data in the Pathology Atlas is based on the integration of publicly available data from The Cancer Genome Atlas and data generated within the framework of the Human Protein Atlas and analyzed transcriptomics and survival in 176 PDAC patients. The results are presented in the form of Kaplan–Meier plots and only differences in survival with a high statistical significance ( $p < 0.001$ ) are taken into consideration. We also performed additional searches of the literature for studies using different patient cohorts that validate the conclusions drawn from the Pathology Atlas.

As expected, increased expression of YAP is associated significantly with an unfavorable prognosis (survival) in PDAC patients who were included in the Pathology Atlas<sup>49</sup>. Antibody staining, which is also included in the Pathology Atlas, is consistent with the mRNA expression data and is in agreement with other studies<sup>39, 48</sup>, localizes YAP/TAZ to the cancer cells. As illustrated in the Kaplan–Meier plot in Fig. 3, none of the patients of the population with higher levels of YAP mRNA expression ( $n = 36$ ) survived for 5 years, although 32% of the population ( $n = 140$ ) with lower levels of YAP mRNA survived for 5 years or more. In agreement with a recent report using a different cohort of patients<sup>48</sup>, an increase in the expression of YAP is an unfavorable prognostic marker for survival in patients with PDAC.

### MOLECULES DOWNSTREAM AND UPSTREAM OF YAP ARE UNFAVORABLE PROGNOSTIC MARKERS IN PDAC

As indicated in previous sections, YAP and TAZ constitute points of convergence of multiple upstream pathways and in turn, regulate the expression of multiple genes. In most cases, the regulation of gene expression by YAP/TAZ/TEAD occurs via distal enhancer elements<sup>50</sup>. We performed a correlation analysis between mRNA expression of genes that are downstream targets of YAP/TAZ in a variety of cell types and survival of PDAC patients by mining the data that are available in the recently available Pathology Atlas<sup>49</sup>. As highlighted in Fig. 4, multiple YAP/TEAD-regulated genes are significantly associated ( $p < 0.001$ ) with



**Fig. 3** Kaplan–Meier plots for YAP expression in PDAC. The image was reproduced from the Human Protein Atlas (version 17) available at [www.proteinatlas.org](http://www.proteinatlas.org). The link is: <http://www.proteinatlas.org/ENSG00000137693YAP1/pathology/tissue/pancreatic±cancer>.


unfavorable prognosis in PDAC<sup>49</sup>. These include *AJUBA*<sup>50</sup>, *ANLN*<sup>51</sup>, *ANXA3*<sup>50</sup>, *AREG*<sup>28</sup>, *ARHGAP19*<sup>52</sup>, *ARHGAP29*<sup>53</sup>, *AURKA*<sup>19, 50</sup>, *BUB1*<sup>19, 50</sup>, *CCNA2*<sup>50</sup>, *CCND1*<sup>50, 54</sup>, *CDK6*<sup>50, 55</sup>, *CEP55*<sup>50</sup>, *CXCL5*<sup>31, 47, 50</sup>, *DKK1*<sup>50, 56</sup>, *EDN2*<sup>50, 57</sup>, *EZR*<sup>50, 58</sup>, *FOXM1*<sup>59</sup>, *HBEGF*<sup>50</sup>, *IGFBP2*<sup>60</sup>, *JAG1*<sup>50, 61</sup>, *KIF2C*<sup>50</sup>, *KIF18B*<sup>50</sup>, *KIF23*<sup>50</sup>, *MSLN*<sup>50, 62</sup>, *NOTCH2*<sup>63</sup>, *PRMT5*<sup>50</sup>, *RRM2*<sup>50</sup>, *SERP1*<sup>50</sup>, *RHAMM*<sup>23</sup>, and *ZWILCH*<sup>50</sup>. Each reference identifies the study or studies that connected the expression of the corresponding gene to YAP/TAZ/TEAD activity. In addition, independent studies using different patient populations demonstrated that the expression of YAP/TAZ/TEAD-regulated genes, including *ANLN*<sup>64</sup>, *AREG*<sup>65</sup>, *CCND1*<sup>66</sup>, *DKK1*<sup>67</sup>, *EZR*<sup>58</sup>, *FOSL1*<sup>68</sup>, *FOXM1*<sup>69</sup>, *MSLN*<sup>70</sup>, *RHAMM*<sup>71</sup>, *RRM2*<sup>72</sup>, and *SERP1*<sup>73</sup>, is associated with shorter survival in patients with PDAC.

It is important to emphasize that the protein products of YAP/TEAD-regulated genes that are associated with PDAC survival regulate a set of fundamental biological processes in cancer development. For example, *AREG*, *HBEGF*, *CCND1*, and *RRM2* stimulate cell proliferation; *AURKA*, *BUB1*, *CEP55*, *KIF23*, and *ZWILCH* participate in mitosis<sup>68, 74</sup>. YAP cooperates with *FOXM1* to promote chromosome instability<sup>59</sup>, and *CXCL5* mediates communication between cancer cells and myeloid-derived suppressor cells<sup>47</sup>, which contributes to the immunosuppressive microenvironment characteristic of PDAC. Other YAP/TEAD-regulated gene products are involved in the regulation of developmental pathways, including *NOTCH*, *DKK1/WNT*, and the Hippo pathway itself via *AJUBA*<sup>75</sup>. *AURKA* also inhibits *LKB1/AMPK* signaling thereby leading to YAP activation (see below). Furthermore, proteins that are encoded by the YAP-regulated genes *EZR* and *IGFBP2* (ezrin and *IGFBP2*, respectively) promote metastasis and epithelial-to-mesenchymal transition (EMT) in pancreatic cancer cells<sup>76</sup>. In turn, EMT contributes to the loss of cell polarity and thus to inhibition of the Hippo pathway, thereby reinforcing YAP activation. It is also of interest that the expression of some YAP/TEAD-regulated genes, including *CTGF* (encoding for connective tissue growth factor) have not been identified as prognostic markers of PDAC, but are likely to play a role in pancreatic carcinogenesis<sup>77</sup>.


In addition to *AREG* (amphiregulin) and *HBEGF* (heparin-binding EGF), which stimulate YAP/TEAD signaling via autocrine/paracrine stimulation of *EGFR*<sup>78</sup> as part of positive feedback loops, other *EGFR* ligands, including *TGF $\alpha$*  and *epiregulin* (*EPEG*) that stimulate YAP activity are also associated with shorter overall survival in PDAC (Fig. 4). Similarly, the increased expression of *MET*<sup>79</sup>, *ITGA2*<sup>80</sup>, *IQGAP1*<sup>81</sup>, *EZR*<sup>82</sup>, *MUC1*<sup>83</sup>, *PRKC*<sup>84</sup>, and *YES1*<sup>85</sup> which enhance YAP co-transcriptional activity through different mechanisms, is associated with shorter survival in patients with PDAC (Fig. 4). Interestingly, the activator protein-1 (AP-1, dimer of *JUN* and *FOS* proteins) factors have been shown to potentiate YAP/TAZ/TEAD-dependent gene expression via enhancers rather than promoters<sup>50</sup>. In line with the notion that YAP/TAZ is at the center of a signaling network that is associated with patient survival, the expression of *FOSL1*, a component of AP-1, is also strongly associated ( $p < 0.001$ ) with an unfavorable prognosis in PDAC, as has also been shown recently in an independent report<sup>68</sup>.

GPCR signaling is one of the major upstream signals that regulate YAP/TAZ activation in a variety of systems, including PDAC<sup>31</sup>. In this context, the expression of genes encoding the lysophosphatidic acid (LPA) receptor *GPR87*<sup>86</sup>, the purinergic GPCR *P2Y<sub>2</sub>R*<sup>87</sup> and the GPCR agonist *EDN2* (endothelin 2)<sup>57</sup>, a downstream target of YAP, are also associated with an unfavorable prognosis in PDAC. A recent independent study confirmed that overexpression of *GPR87* is correlated with a poor prognosis in PDAC<sup>88</sup>. By contrast, the expression of *GRK6*, which phosphorylates GPCRs thus opposing their signaling output<sup>89</sup>, is associated with a favorable survival prognosis in PDAC (Fig. 4).

As mentioned above, the organization of the actin cytoskeleton is a master regulator of YAP/TAZ nuclear localization and activity<sup>90, 91</sup>. Interestingly, a number of proteins that are encoded



**Fig. 4** YAP signaling is associated with unfavorable prognosis for PDAC. Multiple YAP/TEAD-regulated genes are associated with unfavorable survival of PDAC patients (indicated in red). Growth factors (TGF $\alpha$ , EPEG, and HBEGF), a specific integrin (*ITGA2*), GPCRs (*P2Y<sub>2</sub>R*, *GPR87*) or an inhibitor of the Hippo pathway (*MUC1*) that stimulate YAP activity are also associated with unfavorable survival in PDAC. Conversely, YAP inhibitory pathways, including STRAD/LKB-1, PKA/LATS, and TSC/mTORC1 are associated with a favorable prognosis (indicated in blue). The key feature is that each component of the network has an impact on survival of PDAC patients, as derived from the Pathology Atlas<sup>49</sup>, as well as additional references cited in the text. An unfavorable prognosis for PDAC is in red and a favorable prognosis for PDAC is in blue. All prognostic associations are highly statistically significant ( $p < 0.001$ ). Further details are in the text



**Fig. 5** Kaplan–Meier plots for gene expression of the YAP signaling network in PDAC. Images were reproduced from the Human Protein Atlas (version 17) available at [www.proteinatlas.org](http://www.proteinatlas.org). The links to the specific genes shown are as follows: AHA1, <http://www.proteinatlas.org/ENSG00000124942AHA1/pathology/tissue/pancreatic±cancer>, ANLN, <http://www.proteinatlas.org/ENSG00000011426ANLN/pathology/tissue/pancreatic±cancer>, CDK6, <http://www.proteinatlas.org/ENSG00000105810-CDK6/pathology/tissue/pancreatic±cancer>, EPS8, <http://www.proteinatlas.org/ENSG00000151491-EPS8/pathology/tissue/pancreatic±cancer>, JAG1, <http://www.proteinatlas.org/ENSG00000101384-JAG1/pathology/tissue/pancreatic±cancer>, PKA, <http://www.proteinatlas.org/ENSG00000072062-PRKACA/pathology/tissue/pancreatic±cancer>

by YAP/TEAD-regulated genes also influence the organization of the actin cytoskeleton, suggesting the existence of feedback loops. The epidermal growth factor receptor pathway substrate 8 (*Eps8*), a regulator of actin remodeling that is up-regulated in >70% of PDACs and induces YAP translocation to the nucleus and transcriptional activation<sup>92</sup>, is associated with an unfavorable prognosis in PDAC<sup>49</sup>. ANLN and AHNK, proteins that are implicated in actin cytoskeleton organization<sup>93</sup> and thus, potentially in YAP regulation, are also associated with unfavorable survival in PDAC. Indeed, *AHNK*, *ANLN*, *CDK6*, *EPS8*, and *JAG1* are among the genes with the highest significance associated with unfavorable prognoses in PDAC (Kaplan–Meier plots in Fig. 5;  $p < 4.1 \times 10^{-6}$ ) and are all either upstream or downstream of YAP/TEAD (Fig. 4).

### PATHWAYS THAT OPPOSE YAP SIGNALING ARE FAVORABLE PROGNOSTIC MARKERS IN PDAC

In recent years, it has become apparent that, in addition to the cascade of Hippo kinases, other important pathways also inhibit YAP/TAZ functions. AMP-activated protein kinase (AMPK) is a well-known sensor of cellular energy that is activated when ATP concentrations decrease and 5'-AMP concentrations increase<sup>94</sup>. AMPK opposes YAP activity at different levels, including direct phosphorylation of YAP at Ser-94, a key residue for the interaction between YAP and TEAD<sup>35, 95</sup>. The tumor suppressor LKB-1/STK11 is the major kinase for phosphorylating the AMPK activation loop at Thr-172<sup>96</sup>. Interestingly, STE20-related adaptor (STRAD), a co-factor that allosterically stimulates LKB-1 activity and thus promotes AMPK activity, is a favorable prognostic marker in pancreatic cancer (Fig. 4). Furthermore, the protein kinases of the MARK family (e.g., MARK1) that also function downstream of LKB-1 and repress YAP activity<sup>97</sup> are also associated with a favorable prognosis in pancreatic cancer.

A number of other studies have indicated that the cAMP/PKA pathway also inhibits YAP activity<sup>98</sup>, at least in part via stimulation of LATS kinases<sup>99</sup>. Accordingly, expression of PKA is associated with a favorable prognosis in PDAC, presumably via inhibition of YAP function (Fig. 4).

As mentioned above, mTORC1 is part of an amplification loop that leads to YAP expression and enhanced activity. The heterodimer of the tumor suppressors TSC2 (tuberous sclerosis 2, also known as tuberlin) and TSC1 (tuberous sclerosis 1, also known as hamartin) opposes mTORC1 signaling<sup>100, 101</sup> by acting as a GTPase-activator protein for the small G protein Rheb, a potent activator of mTORC1 signaling in its GTP-bound state<sup>102, 103</sup>. Importantly, increased expression of *TSC2* and *TSC1* is associated with a favorable prognosis for patients with PDAC (Fig. 4).

### TARGETING THE YAP SIGNAL TRANSDUCTION PATHWAY

As a result of the developments discussed in this article, there is intense interest in targeting YAP/TAZ in PDAC therapy and chemoprevention. Although inhibition of the activity of transcription factors or their co-activators is a challenging strategy, recent preclinical and epidemiological evidence suggest new approaches for targeting the YAP/TAZ signal transduction pathway.

Many studies have shown that the mevalonate pathway is markedly up-regulated in several epithelial cancers via mutant p53<sup>95, 104, 105</sup> and Akt/mTORC1<sup>95</sup>. Statins are specific inhibitors of 3-hydroxy-methylglutaryl (HMG) CoA reductase<sup>106</sup> which is the rate-limiting enzyme in the generation of mevalonate, the first step in the biosynthesis of isoprenoids leading to farnesyl pyrophosphate (FPP), geranylgeranyl pyrophosphate (GG-PP) and cholesterol. Transfer of the geranylgeranyl moiety to a COOH-terminal cysteine of Rho GTPases is critical for their function in signal transduction. In turn, active Rho (i.e., Rho-GTP)

is essential for YAP/TAZ activation via actin cytoskeletal organization. Statins, which are usually well tolerated and generally safe, are used to treat hypercholesterolemia and prevent cardiovascular diseases. Although initially inconsistent, mounting epidemiological studies indicate that the use of statins is associated with a reduced risk and beneficial effects in PDAC<sup>107–111</sup>, especially in men<sup>110, 111</sup>. For example, a recent large study demonstrated that statin use was associated with a 34% reduced risk of PDAC, with a stronger association in male subjects<sup>110</sup>. In addition to their potential use in primary prevention, statins have also been shown to improve the survival of patients after resection of primary PDAC tumors, indicating a possible role of statins in the prevention of secondary PDAC<sup>107, 108, 112</sup>. Of great interest, a high-throughput screen of compounds capable of altering the subcellular localization of YAP led to the identification of statins as potential YAP inhibitors via the inhibition of Rho<sup>113</sup>. An independent study that examined the regulation of the expression of the receptor for hyaluronan-mediated motility (RHAMM) also led to the discovery that statins inhibit YAP/TAZ activity<sup>23</sup>. Consequently, statins provide a plausible strategy for targeting YAP/TAZ function and thus, an explanation for the mechanism by which these drugs appear to exert beneficial effects in PDAC. In view of these considerations, prospective clinical trials targeting YAP/TAZ with statins in primary or secondary PDAC chemoprevention are needed.

Metformin (1,1-dimethylbiguanide hydrochloride) is the most widely prescribed drug for the treatment of type 2 diabetes mellitus (T2DM) worldwide<sup>94, 114</sup>. Epidemiological studies suggest that administration of metformin may reduce cancer incidence and mortality in diabetic patients<sup>115</sup>. A recent meta-analysis indicated that metformin improved survival in PDAC patients with resection and patients with locally advanced tumors, but not in patients with metastatic PDAC<sup>116</sup>. In mechanistic studies, we demonstrated that metformin potently stimulated AMPK activation in intact human PDAC cells that were cultured with physiological concentrations of glucose in the medium<sup>117, 118</sup>, and inhibited mTORC1, ERK and mitogenic signaling via AMPK at low concentrations<sup>117–119</sup>. Metformin also inhibited the growth of PDAC xenografts<sup>29, 120</sup> and the development of PanINs and PDAC in KC mice<sup>121</sup>. As indicated above, AMPK, a well-known sensor of cellular energy<sup>94</sup>, opposes YAP function via direct phosphorylation of YAP at Ser-94<sup>122, 123</sup> as well as by phosphorylation of HMG-CoA reductase at Ser-872, which inhibits mevalonic acid synthesis<sup>124</sup>. These studies imply a connection between cellular energy status, lipid metabolism, AMPK and YAP/TAZ function. Because statins and metformin interfere with YAP function through different mechanisms, it is plausible that a combination of these agents additively or synergistically may suppress YAP/TAZ activity and thereby exerts cancer-preventive activity at low concentrations of each agent.

As indicated in Fig. 4, YAP/TAZ leads to an increase of the Notch pathway, which is likely to contribute to the oncogenic effects of YAP/TAZ. Indeed, pharmacological inhibitors of Notch activation reduced PDAC xenograft growth in preclinical models<sup>125</sup> but were not effective in PDAC patients with advanced disease<sup>126</sup>. Upstream of YAP, inhibitors of EGFR have already shown a small favorable effect in PDAC<sup>127</sup>, however, other pathways can bypass EGFR. mTORC1 is part of an amplification loop that leads to YAP expression and enhanced activity, and the heterodimer of TSC2 and TSC1 which opposes mTORC1 signaling<sup>100, 101</sup>, is associated with a favorable prognosis for patients with PDAC. A number of mTOR inhibitors are available but their efficacy decreases with time and YAP provides one route for escape<sup>128</sup>. There is a clear need for further studies using combinations of drugs that target the YAP network at different levels to determine their possible anticancer activity.

A number of small molecule tyrosine kinase inhibitors, including dasatinib and pazopanib, induce YAP/TAZ phosphorylation and

cytoplasmic degradation and reduce their nuclear translocation, suggesting another approach for restraining YAP/TAZ activity<sup>129</sup>. Although these inhibitors frequently induce drug resistance via enhancement of compensatory pathways<sup>130</sup> these tyrosine kinase inhibitors could be considered as part of a combinatorial strategy.

A number of laboratories have searched for compounds that inhibit the nuclear localization of YAP and/or the interaction of YAP with TEAD<sup>131</sup>. Verteporfin (trade name Visudyne), a member of the porphyrin family, is used in photodynamic therapy of ophthalmological diseases to destroy new abnormal vessels with few side effects. Verteporfin, without light activation, has been reported to inhibit YAP/TEAD complex formation, thereby acting as a suppressor of cell growth<sup>132–134</sup>. However, in addition to its putative inhibitory effect on YAP/TEAD function, verteporfin also induces protein cross-linking via a non-enzymatic mechanism<sup>135, 136</sup>. Thus, verteporfin provides a plausible strategy for interfering with YAP/TEAD function within cells, but it has additional cellular effects and therefore its specificity as a YAP/TEAD antagonist has been questioned.

Mammalian Vestigial-like 4 (VGLL4) is a tumor suppressor that does not bind directly to DNA but competes with YAP for binding TEADs<sup>137, 138</sup>. A peptide capable of mimicking the function of VGLL4 suppressed tumor growth *in vitro* and *in vivo*, implying that disrupting the YAP-TEAD interaction by a VGLL4-mimicking peptide may be a therapeutic strategy for inhibiting YAP-mediated cell proliferation<sup>137</sup>. However, this approach has limitations, including the permeability of the peptide across the plasma membrane and its stability. Importantly, crystal structures of YAP/TEAD<sup>139</sup> and TAZ/TEAD<sup>140</sup> complexes have been solved, opening new avenues for computational modeling of compounds that disrupt these molecular complexes within intact cells<sup>141, 142</sup>.

## CONCLUSION AND IMPLICATIONS

PDAC is generally a fatal disease with no efficacious treatment modalities. It is important that strategies to prevent the disease be explored, especially since its incidence is projected to increase markedly in the next decade. YAP and TAZ, the major downstream targets of the Hippo tumor suppressor pathway (Fig. 1), are also regulated by a multitude of other inputs, including KRAS (Fig. 2). The data discussed in this article indicate that not only YAP (Fig. 3) but also many components of the YAP network are associated with overall survival in PDAC (Fig. 4). Indeed, multiple downstream targets of YAP/TAZ/TEAD are associated with unfavorable survival of PDAC patients. Similarly, multiple components that stimulate YAP activity, including AP-1 which synergizes with YAP (*FOSL1*) and growth factors (TGF $\alpha$ , EPEG, and HBEGF), GPCRs (*P2Y<sub>2</sub>R*, *GPR87*), a specific integrin (*ITGA2*) or an inhibitor of the Hippo pathway (*MUC1*), are all convincingly associated with unfavorable survival in PDAC (Fig. 4). In sharp contrast, increased expression of YAP inhibitory pathways (LKB-1, PKA, TSC) portends a favorable prognosis. All of these associations which have been derived from the recently published interactive open-access database ([www.proteinatlas.org/pathology](http://www.proteinatlas.org/pathology)) that allows genome-wide exploration of the impact of individual proteins on survival outcomes, emphasize that increased expression of the YAP signaling web correlates with poorer survival of patients with PDAC. This analysis convincingly supports the notion that the YAP network is a target for therapeutic and preventive strategies in PDAC. The association of patient survival to the YAP/TAZ signaling network strongly suggests a need for novel combinatorial strategies for targeting the YAP network in PDAC, one of the most lethal diseases.

Upstream of YAP, EGFR inhibitors have already shown a small favorable effect in PDAC<sup>127</sup>, however, other pathways, including other tyrosine kinase receptors, can bypass EGFR and thus stimulate YAP leading to drug resistance. As indicated above, statins and metformin interfere with YAP function through

different mechanisms, and recent epidemiological studies indicate that their administration is associated with beneficial effects in PDAC<sup>143, 144</sup>. Downstream of YAP, inhibitors of NOTCH pathway activation have shown activity in preclinical models, but were not pursued further because they did not exert any response in advanced PDAC patients. Thus, there are drugs, some of which are FDA-approved and in clinical use, that target the YAP network at different levels, thus providing a rationale for designing combinatorial strategies in both preclinical settings and in future clinical trials for PDAC. Furthermore, there are major efforts to develop potent compounds that disrupt YAP/TEAD and TAZ/TEAD molecular complexes within intact cancer cells.

Given the strong correlation of the YAP signaling network with patient survival that is demonstrated in this article, it is conceivable that a combination of these drugs will suppress YAP/TAZ activity synergistically and thereby exert cancer-preventive activity at low concentrations of each agent, a proposition that warrants further experimental, preclinical and clinical work.

## ACKNOWLEDGEMENTS

E.R. is supported by NIH Grants P01CA163200, R01DK100405, and P30DK41301 and by a Department of Veterans Affairs Grant 1101BX001473 and funds from the endowed Ronald S. Hirschberg Chair of Pancreatic Cancer Research. G.E. is supported by P01CA163200 and funds from the Hirschberg Foundation of Pancreatic Cancer Research. The funders had no role in the preparation of the manuscript.

## AUTHORS' CONTRIBUTIONS

E.R. and G.E. developed the concept; E.R. prepared the manuscript; G.E. and J.S.S. edited the manuscript, J.S.S. and E.R. prepared the illustrations. All authors approved the final version.

## ADDITIONAL INFORMATION

**Conflict of interest:** The authors declare that they have no conflict of interest.

## REFERENCES

1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics. *Cancer J. Clin.* **67**, 7–30 (2017).
2. Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res.* **74**, 2913–2921 (2014).
3. Ying, H. et al. Genetics and biology of pancreatic ductal adenocarcinoma. *Genes Dev.* **30**, 355–385 (2016).
4. Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* **321**, 1801–1806 (2008).
5. Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature* **491**, 399–405 (2012).
6. Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. *Nat. Rev. Cancer* **11**, 761–774 (2011).
7. Bryant, K. L., Mancias, J. D., Kimmelman, A. C. & Der, C. J. KRAS: feeding pancreatic cancer proliferation. *Trends Biochem. Sci.* **39**, 91–100 (2014).
8. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer Cell.* **4**, 437–450 (2003).
9. Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. *Cancer Cell.* **7**, 469–483 (2005).
10. Sudol, M. et al. Characterization of the mammalian YAP (Yes-associated Protein) gene and its role in defining a novel protein module, the WW domain. *J. Biol. Chem.* **270**, 14733–14741 (1995).
11. Kanai, F. et al. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. *EMBO J.* **19**, 6778–6791 (2000).
12. Meng, Z., Moroiishi, T. & Guan, K.-L. Mechanisms of hippo pathway regulation. *Genes Dev.* **30**, 1–17 (2016).
13. Santinon, G., Pocaterra, A. & Dupont, S. Control of YAP/TAZ activity by metabolic and nutrient-sensing pathways. *Trends Cell. Biol.* **26**, 289–299 (2016).
14. Zanconato, F., Cordenonsi, M. & Piccolo, S. YAP/TAZ at the roots of cancer. *Cancer Cell.* **29**, 783–803 (2016).



15. Moroishi, T., Hansen, C. G. & Guan, K.-L. The emerging roles of YAP and TAZ in cancer. *Nat. Rev. Cancer* **15**, 73–79 (2015).
16. Zhang, W. et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. *Sci. Signal.* **7**, ra42–ra42 (2014).
17. Gruber, R. et al. YAP1 and TAZ control pancreatic cancer initiation in mice by direct up-regulation of JAK–STAT3 signaling. *Gastroenterology* **151**, 526–539 (2016).
18. Yang, S. et al. Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3. *Oncotarget* **6**, 36019–36031 (2015).
19. Kapoor, A. et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. *Cell* **158**, 185–197 (2014).
20. Varelas, X. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. *Development* **141**, 1614–1626 (2014).
21. Zheng, Y. et al. Identification of Happyhour/MAP4K as alternative Hpo/Mst-like kinases in the hippo kinase cascade. *Dev. Cell.* **34**, 642–655 (2015).
22. Enzo, E. et al. Aerobic glycolysis tunes YAP/TAZ transcriptional activity. *EMBO J.* **34**, 1349–1370 (2015).
23. Wang, Z. et al. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. *Proc. Natl Acad. Sci. USA* **111**, E89–E98 (2014).
24. Finch-Edmondson, M. L. et al. TAZ protein accumulation is negatively regulated by YAP abundance in mammalian cells. *J. Biol. Chem.* **290**, 27928–27938 (2015).
25. Hayashi, H. et al. An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression. *Cancer Res.* **75**, 4985–4997 (2015).
26. Yu, F.-X. & Guan, K.-L. The Hippo pathway: regulators and regulations. *Genes Dev.* **27**, 355–371 (2013).
27. Straßburger, K., Tiebe, M., Pinna, F., Breuhahn, K. & Teleman, A. A. Insulin/IGF signaling drives cell proliferation in part via Yorkie/YAP. *Dev. Biol.* **367**, 187–196 (2012).
28. Wang, J., Sinnott-Smith, J., Stevens, J. V., Young, S. H. & Rozenfurt, E. Biphasic regulation of Yes-associated Protein (YAP) cellular localization, phosphorylation, and activity by G protein-coupled receptor agonists in intestinal epithelial cells: a novel role for protein kinase D (PKD). *J. Biol. Chem.* **291**, 17988–18005 (2016).
29. Kisfalvi, K., Eibl, G., Sinnott-Smith, J. & Rozenfurt, E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. *Cancer Res.* **69**, 6539–6545 (2009).
30. Rozenfurt, E., Sinnott-Smith, J. & Kisfalvi, K. Crosstalk between Insulin/Insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. *Clin. Cancer Res.* **16**, 2505–2511 (2010).
31. Hao, F. et al. Insulin receptor and GPCR crosstalk stimulates YAP via PI3K and PKD in pancreatic cancer cells. *Mol. Cancer Res.* **15**, 929–941 (2017).
32. Kim, N.-G. & Gumbiner, B. M. Adhesion to fibronectin regulates Hippo signaling via the FAK–Src–PI3K pathway. *J. Cell. Biol.* **210**, 503–515 (2015).
33. Fan, R., Kim, N.-G. & Gumbiner, B. M. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. *Proc. Natl Acad. Sci. USA* **110**, 2569–2574 (2013).
34. Rozenfurt, E., Rey, O. & Waldron, R. T. Protein kinase D signaling. *J. Biol. Chem.* **280**, 13205–13208 (2005).
35. Rozenfurt, E. Protein kinase D signaling: multiple biological functions in health and disease. *Physiology* **26**, 23–33 (2011).
36. Lin, K. C. et al. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation. *Nat. Cell. Biol.* **19**, 996–1002 (2017).
37. Lin, L. et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. *Nat. Genet.* **47**, 250–256 (2015).
38. Di Agostino, S. et al. YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. *EMBO Rep.* **17**, 188–201 (2016).
39. Xie, D. et al. Hippo transducer TAZ promotes epithelial mesenchymal transition and supports pancreatic cancer progression. *Oncotarget* **6**, 35949–35963 (2015).
40. Mello, S. S. et al. A p53 super-tumor suppressor reveals a tumor suppressive p53-Ptn14-Yap axis in pancreatic cancer. *Cancer Cell.* **32**, 460–473.e466 (2017).
41. Hong, X. et al. Opposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover. *EMBO J.* **33**, 2447–2457 (2014).
42. Strnadl, J. et al. eIF5A-PEAK1 signaling regulates YAP1/TAZ protein expression and pancreatic cancer cell growth. *Cancer Res.* **77**, 1997–2007 (2017).
43. Hansen, C. G., Ng, Y. L. D., Lam, W.-L. M., Plouffe, S. W. & Guan, K.-L. The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1. *Cell. Res.* **25**, 1299–1313 (2015).
44. Liang, N. et al. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. *J. Exp. Med.* **211**, 2249–2263 (2014).
45. Shao, D. D. et al. KRAS and YAP1 converge to regulate EMT and tumor survival. *Cell* **158**, 171–184 (2014).
46. Murakami, S. et al. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. *Oncogene* **36**, 1232–1244 (2017).
47. Wang, G. et al. Targeting YAP-dependent MDSC infiltration impairs tumor progression. *Cancer Discov.* **6**, 80–95 (2016).
48. Salcedo Allende, M. T. et al. Overexpression of Yes associated protein 1, an independent prognostic marker in patients with pancreatic ductal adenocarcinoma, correlated with liver metastasis and poor prognosis. *Pancreas* **46**, 913–920 (2017).
49. Uhlen, M. et al. A pathology atlas of the human cancer transcriptome. *Science* **357**, eaan2507 (2017).
50. Zancanato, F. et al. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. *Nat. Cell. Biol.* **17**, 1218–1227 (2015).
51. Calvo, F. et al. Mechano-transduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer associated fibroblasts. *Nat. Cell. Biol.* **15**, 637–646 (2013).
52. Porazinski, S. et al. YAP is essential for tissue tension to ensure vertebrate 3D body shape. *Nature* **521**, 217–221 (2015).
53. Qiao, Y. et al. YAP regulates actin dynamics through ARHGAP29 and promotes metastasis. *Cell Rep.* **19**, 1495–1502 (2017).
54. Mizuno, T. et al. YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. *Oncogene* **31**, 5117–5122 (2012).
55. Xie, Q. et al. YAP/TEAD-mediated transcription controls cellular senescence. *Cancer Res.* **73**, 3615–3624 (2013).
56. Park, H. W. et al. Alternative Wnt signaling activates YAP/TAZ. *Cell* **162**, 780–794 (2015).
57. Schütte, U. et al. Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma. *Transl. Oncol.* **7**, 309–321 (2014).
58. Piao, J. et al. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas. *Exp. Mol. Pathol.* **98**, 1–6 (2015).
59. Weiler, S. M. E. et al. Induction of chromosome instability by activation of Yes-associated protein and forkhead box M1 in liver cancer. *Gastroenterology* **152**, 2037–2051 (2017). e2022.
60. Xin, M. et al. Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size. *Sci. Signal.* **4**, ra70–ra70 (2011).
61. Tschaharganeh, D. F. et al. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. *Gastroenterology* **144**, 1530–1542.e1512 (2013).
62. Ren, Y. R., Patel, K., Paun, B. C. & Kern, S. E. Structural analysis of the cancer-specific promoter in mesothelin and in other genes overexpressed in cancers. *J. Biol. Chem.* **286**, 11960–11969 (2011).
63. Wu, N. et al. The Hippo signaling functions through the Notch signaling to regulate intrahepatic bile duct development in mammals. *Lab. Invest.* **97**, 843–853 (2017).
64. Idichi, T. et al. Regulation of actin-binding protein ANLN by antitumor miR-217 inhibits cancer cell aggressiveness in pancreatic ductal adenocarcinoma. *Oncotarget* **8**, 53180–53193 (2017).
65. Wang, L. et al. Expression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma. *Diagn. Pathol.* **11**, 60 (2016).
66. Bachmann, K. et al. Cyclin D1 is a strong prognostic factor for survival in pancreatic cancer: analysis of CD G870A polymorphism, FISH and immunohistochemistry. *J. Surg. Oncol.* **111**, 316–323 (2015).
67. Han, S.-x. et al. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. *Oncotarget* **6**, 19907–19917 (2015).
68. Vallejo, A. et al. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. *Nat. Commun.* **8**, 14294 (2017).
69. Dai, J., Yang, L., Wang, J., Xiao, Y. & Ruan, Q. Prognostic value of FOXM1 in patients with malignant solid tumor: a meta-analysis and system review. *Dis. Markers* **2015**, 352478 (2015).
70. Winter, J. M. et al. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. *PLoS ONE* **7**, e40157 (2012).
71. Cheng, X.-B., Sato, N., Kohi, S., Koga, A. & Hirata, K. Receptor for hyaluronic acid-mediated motility is associated with poor survival in pancreatic ductal adenocarcinoma. *J. Cancer* **6**, 1093–1098 (2015).
72. Itoi, T. et al. Ribonucleotide reductase subunit M2 mRNA expression in pre-treatment biopsies obtained from unresectable pancreatic carcinomas. *J. Gastroenterol.* **42**, 389–394 (2007).
73. Ma, Q., Wu, X., Wu, J., Liang, Z. & Liu, T. SERP1 is a novel marker of poor prognosis in pancreatic ductal adenocarcinoma patients via anti-apoptosis and regulating SRPRB/NF- $\kappa$ B axis. *Int. J. Oncol.* **51**, 1104–1114 (2017).

74. Yang, S., Zhang, L., Chen, X., Chen, Y. & Dong, J. Oncoprotein YAP regulates the spindle checkpoint activation in a mitotic phosphorylation-dependent manner through up-regulation of BubR1. *J. Biol. Chem.* **290**, 6191–6202 (2015).
75. Jagannathan, R. et al. AJUBA LIM proteins limit hippo activity in proliferating cells by sequestering the hippo core kinase complex in the cytosol. *Mol. Cell. Biol.* **36**, 2526–2542 (2016).
76. Liu, H. et al. Silencing IGF2BP2 decreases pancreatic cancer metastasis and enhances chemotherapeutic sensitivity. *Oncotarget* **8**, 61674–61686 (2017).
77. Neesse, A. et al. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. *Proc. Natl Acad. Sci. USA* **110**, 12325–12330 (2013).
78. Wagner, M. et al. Transgenic overexpression of amphiregulin induces a mitogenic response selectively in pancreatic duct cells. *Gastroenterology* **122**, 1898–1912 (2002).
79. Tao, L., Xiang, D., Xie, Y., Bronson, R. T. & Li, Z. Induced p53 loss in mouse luminal cells causes clonal expansion and development of mammary tumours. *Nat. Commun.* **8**, 14431 (2017).
80. Wong, K.-F., Liu, A. M., Hong, W., Xu, Z. & Luk, J. M. Integrin  $\alpha 2 \beta 1$  inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma. *Oncotarget* **7**, 77683–77695 (2016).
81. Anakk, S. et al. Bile acids activate YAP to promote liver carcinogenesis. *Cell Rep.* **5**, 1060–1069 (2013).
82. Quan, C., Yan, Y., Qin, Z., Lin, Z. & Quan, T. Ezrin regulates skin fibroblast size/mechanical properties and YAP-dependent proliferation. *J. Cell. Commun. Signal.* <https://doi.org/10.1007/s12079-017-0406-6> (2017).
83. Alam, M. et al. MUC1-C represses the crumbs complex polarity factor CRB3 and downregulates the hippo pathway. *Mol. Cancer Res.* **14**, 1266–1276 (2016).
84. Wang, Y. et al. PKC[ $\alpha$ ] regulates nuclear YAP1 localization and ovarian cancer tumorigenesis. *Oncogene* **36**, 534–545 (2017).
85. Rosenbluh, J. et al.  $\beta$ -catenin driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. *Cell* **151**, 1457–1473 (2012).
86. Tabata, K.-i., Baba, K., Shiraiishi, A., Ito, M. & Fujita, N. The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. *Biochem. Biophys. Res. Commun.* **363**, 861–866 (2007).
87. Khalafalla, F. G. et al. P2Y2 nucleotide receptor prompts human cardiac progenitor cell activation by modulating hippo signaling. *Circ. Res.* **121**, 1224–1236 (2017).
88. Wang, L. et al. Overexpression of G protein-coupled receptor GPR87 promotes pancreatic cancer aggressiveness and activates NF- $\kappa$ B signaling pathway. *Mol. Cancer* **16**, 61 (2017).
89. Li, L. et al. G protein-coupled receptor kinases of the GRK4 protein subfamily phosphorylate inactive G Protein-coupled Receptors (GPCRs). *J. Biol. Chem.* **290**, 10775–10790 (2015).
90. Dupont, S. et al. Role of YAP/TAZ in mechanotransduction. *Nature* **474**, 179–183 (2011).
91. Aragona, M. et al. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. *Cell* **154**, 1047–1059 (2013).
92. Giampietro, C. et al. The actin-binding protein EPS8 binds VE-cadherin and modulates YAP localization and signaling. *J. Cell. Biol.* **211**, 1177–1192 (2015).
93. Benaud, C. et al. AHNK interaction with the annexin 2/S100A10 complex regulates cell membrane cytoarchitecture. *J. Cell. Biol.* **164**, 133–144 (2004).
94. Kahn, B. B., Alquier, T., Carling, D. & Hardie, D. G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. *Cell. Metab.* **1**, 15–25 (2005).
95. Kuzu, O. F., Noory, M. A. & Robertson, G. P. The role of cholesterol in cancer. *Cancer Res.* **76**, 2063–2070 (2016).
96. Hezel, A. F. & Bardeesy, N. LKB1; linking cell structure and tumor suppression. *Oncogene* **27**, 6908–6919 (2008).
97. Mohseni, M. et al. A genetic screen identifies an LKB1/PAR1 signaling axis controlling the Hippo/YAP pathway. *Nat. Cell. Biol.* **16**, 108–117 (2014).
98. Yu, F.-X. et al. Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. *Genes Dev.* **27**, 1223–1232 (2013).
99. Kim, M. et al. cAMP/PKA signalling reinforces the LATS–YAP pathway to fully suppress YAP in response to actin cytoskeletal changes. *EMBO J.* **32**, 1543–1555 (2013).
100. Tee, A. R. et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. *Proc. Natl Acad. Sci. USA* **99**, 13571–13576 (2002).
101. Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J. & Cantley, L. C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. *Mol. Cell.* **10**, 151–162 (2002).
102. Garami, A. et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. *Mol. Cell.* **11**, 1457–1466 (2003).
103. Zhang, Y. et al. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. *Nat. Cell. Biol.* **5**, 578–581 (2003).
104. Freed-Pastor, William A. et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. *Cell* **148**, 244–258 (2012).
105. Clendening, J. W. et al. Dysregulation of the mevalonate pathway promotes transformation. *Proc. Natl Acad. Sci. USA* **107**, 15051–15056 (2010).
106. Istvan, E. S. & Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. *Science* **292**, 1160–1164 (2001).
107. Jeon, C. Y. et al. The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis. *PLoS ONE* **10**, e0121783 (2015).
108. Wu, B. U. et al. Impact of statin use on survival in patients undergoing resection for early-stage pancreatic cancer. *Am. J. Gastroenterol.* **110**, 1233–1239 (2015).
109. Chen, M.-J. et al. Statins and the risk of pancreatic cancer in Type 2 diabetic patients—A population-based cohort study. *Int. J. Cancer* **138**, 594–603 (2016).
110. Walker, E. J., Ko, A. H., Holly, E. A. & Bracci, P. M. Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control study. *Cancer* **121**, 1287–1294 (2015).
111. Carey, F. J. et al. The differential effects of statins on the risk of developing pancreatic cancer: a case-control study in two centres in the United Kingdom. *Dig. Dis. Sci.* **58**, 3308–3312 (2013).
112. Lee, H. S. et al. Statin use and its impact on survival in pancreatic cancer patients. *Medicine* **95**, e3607 (2016).
113. Sorrentino, G. et al. Metabolic control of YAP and TAZ by the mevalonate pathway. *Nat. Cell. Biol.* **16**, 357–366 (2014).
114. Witters, L. A. The blooming of the French lilac. *J. Clin. Invest.* **108**, 1105–1107 (2001).
115. Gandini, S. et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. *Cancer Prev. Res.* **7**, 867–885 (2014).
116. Li, X., Li, T., Liu, Z., Gou, S. & Wang, C. The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis. *Sci. Rep.* **7**, 5825 (2017).
117. Sinnott-Smith, J., Kisfalvi, K., Kui, R. & Rozenfurt, E. Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK. *Biochem. Biophys. Res. Commun.* **430**, 352–3527 (2013).
118. Soares, H. P., Ni, Y., Kisfalvi, K., Sinnott-Smith, J. & Rozenfurt, E. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. *PLoS ONE* **8**, e57289 (2013).
119. Ming, M. et al. Dose-dependent AMPK-dependent and independent mechanisms of berberine and metformin inhibition of mTORC1, ERK, DNA synthesis and proliferation in pancreatic cancer cells. *PLoS ONE* **9**, e114573 (2014).
120. Kisfalvi, K., Moro, A., Sinnott-Smith, J., Eibl, G. & Rozenfurt, E. Metformin inhibits the growth of human pancreatic cancer xenografts. *Pancreas* **42**, 781–785 (2013).
121. Chen, K. et al. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. *Mol. Cancer* **16**, 131 (2017).
122. Mo, J.-S. et al. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. *Nat. Cell. Biol.* **17**, 500–510 (2015).
123. Wang, W. et al. AMPK modulates Hippo pathway activity to regulate energy homeostasis. *Nat. Cell. Biol.* **17**, 490–499 (2015).
124. Omkumar, R. V., Darnay, B. G. & Rodwell, V. W. Modulation of Syrian hamster 3-hydroxy-3-methylglutaryl-CoA reductase activity by phosphorylation. Role of serine 871. *J. Biol. Chem.* **269**, 6810–6814 (1994).
125. Mizuma, M. et al. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. *Mol. Cancer Ther.* **11**, 1999–2009 (2012).
126. De Jesus-Acosta, A. et al. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. *Invest. New. Drugs* **32**, 739–745 (2014).
127. Ko, A. H. et al. A multicenter, open-label phase II clinical trial of combined MEK plus EGFR inhibition for chemotherapy-refractory advanced pancreatic adenocarcinoma. *Clin. Cancer Res.* **22**, 61–68 (2016).
128. Muranen, T. et al. ERK and p38 MAPK activities determine sensitivity to PI3K/mTOR inhibition via regulation of MYC and YAP. *Cancer Res.* **76**, 7168–7180 (2016).
129. Oku, Y. et al. Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers. *FEBS Open Bio.* **5**, 542–549 (2015).

130. Rozenfurt, E., Soares, H. P. & Sinnett-Smith, J. Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. *Mol. Cancer Ther.* **13**, 2477–2488 (2014).
131. Santucci, M. et al. The Hippo pathway and YAP/TAZ–TEAD protein–protein interaction as targets for regenerative medicine and cancer treatment. *J. Med. Chem.* **58**, 4857–4873 (2015).
132. Liu-Chittenden, Y. et al. Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAP. *Genes Dev.* **26**, 1300–1305 (2012).
133. Perra, A. et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. *J. Hepatol.* **61**, 1088–1096 (2014).
134. Al-Moujahed, A. et al. Verteporfin inhibits growth of human glioma in vitro without light activation. *Sci. Rep.* **7**, 7602 (2017).
135. Konstantinou, E. K. et al. Verteporfin-induced formation of protein cross-linked oligomers and high molecular weight complexes is mediated by light and leads to cell toxicity. *Sci. Rep.* **7**, 46581 (2017).
136. Zhang, H. et al. Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1(). *Sci. Signal.* **8**, ra98–ra98 (2015).
137. Jiao, S. et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. *Cancer Cell.* **25**, 166–180 (2014).
138. Zhang, Y. et al. VGLL4 selectively represses YAP-dependent gene induction and tumorigenic phenotypes in breast cancer. *Sci. Rep.* **7**, 6190 (2017).
139. Li, Z. et al. Structural insights into the YAP and TEAD complex. *Genes Dev.* **24**, 235–240 (2010).
140. Kaan, H. Y. K. et al. Crystal structure of TAZ-TEAD complex reveals a distinct interaction mode from that of YAP–TEAD complex. *Sci. Rep.* **7**, 2035 (2017).
141. Kaan, H. Y. K., Sim, A. Y. L., Tan, S. K. J., Verma, C. & Song, H. Targeting YAP/TAZ–TEAD protein–protein interactions using fragment-based and computational modeling approaches. *PLoS ONE* **12**, e0178381 (2017).
142. Pobbati, A. V. et al. Targeting the central pocket in human transcription factor TEAD as a potential cancer therapeutic strategy. *Structure* **23**, 2076–2086 (2015).
143. Amin, S. et al. Metformin improves survival in patients with pancreatic ductal adenocarcinoma and pre-existing diabetes: a propensity score analysis. *Am. J. Gastroenterol.* **111**, 1350–1357 (2016).
144. Mei, Z. et al. Effects of statins on cancer mortality and progression: a systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals. *Int. J. Cancer* **140**, 1068–1081 (2017).



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018